Biocon Cautiously Optimistic On Earnings Prospects Amid Slower Approvals
Executive Summary
India’s biggest biotech firm has said it is “cautiously optimistic” about its performance this financial year after fourth-quarter net profit slid due to an exceptional item in the previous year, but reports progress on multiple fronts for its large biosimilar portfolio.
You may also be interested in...
Roche Faces Probe On Claims It Derailed Biosimilar Herceptin
Did Roche engage in abusive market conduct aimed at keeping trastuzumab biosimilar versions at bay in India? The Competition Commission of India has sought a detailed investigation into a string of serious allegations brought about by Biocon and Mylan and has held that some of the Swiss firm’s actions prima facie appear to be aimed at adversely affecting the penetration of biosimilars in the country.
Mylan Clears Runway For US Herceptin Biosimilar Launch
The generic drug manufacturer is poised to be first to market with a biosimilar version of Roche’s blockbuster breast cancer therapy after reaching a license agreement. The date of a potential launch remains confidential.
Top US Court Lifts Discovery Stay On Price-Fixing
The US Supreme Court has lifted a stay on document discovery in a multi-state lawsuit in which dozens of generics companies – including Teva, Mylan and Pfizer – are accused of price fixing. The ruling will allow a swathe of documents to be released in what Connecticut’s attorney general has said is potentially “the largest cartel case” in US history.